4702Programmes de vaccination sur-mesure à l’aide d’un design centré sur l’humainPublications · 27 juillet 2022
4703Desenho centrado nas pessoas para adaptação dos programas de vacinaçãoPublications · 27 juillet 2022
4705Report of the fifth meeting of the WHO Strategic and Technical Advisory Group of Experts for maternal, newborn, child and adolescent health and nutrition, 10–12 May 2022Publications · 26 juillet 2022
4706Modelo centrado en las personas para adaptar los programas de inmunizaciónPublications · 26 juillet 2022
4707Progress on drinking water, sanitation and hygiene in schools: 2000-2021 data updatePublications · 26 juillet 2022
4708Guidelines on long-acting injectable cabotegravir for HIV prevention: web annex G: evidence-to-decision making tablePublications · 26 juillet 2022
4710Guidelines on long-acting injectable cabotegravir for HIV prevention: web annex A: declarations of interest for the guideline development group and external peer reviewersPublications · 26 juillet 2022
4711Își pot permite oamenii să plătească pentru servicii de sănătate? Noi dovezi privind protecția financiară în RomâniaPublications · 26 juillet 2022
4712Guidelines on long-acting injectable cabotegravir for HIV prevention: web annex D: projected population impact of expanding PrEP coverage by offering long-acting injectable PrEP in different settings: model comparison analysisPublications · 26 juillet 2022
4713Guidelines on long-acting injectable cabotegravir for HIV prevention: web annex C: systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis, including long-acting injectable cabotegravir, to prevent HIV infectionPublications · 26 juillet 2022
4714Can people afford to pay for health care? New evidence on financial protection in RomaniaPublications · 26 juillet 2022
4715Guidelines on long-acting injectable cabotegravir for HIV prevention: web annex F: perspectives and preferences regarding long-acting injectable cabotegravir for HIV prevention among pre-exposure prophylaxis (PrEP) providers: a global survey and in-depth interviewsPublications · 26 juillet 2022
4716Guidelines on long-acting injectable cabotegravir for HIV prevention: web annex B: systematic review, meta-analysis and GRADE evidence profile on safety, efficacy, and effectiveness of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) to reduce the risk of HIV acquisitionPublications · 26 juillet 2022
4717Standard operating procedures for supply chain management of health products for neglected tropical diseases amenable to preventive chemotherapyPublications · 26 juillet 2022
4718Guidelines on long-acting injectable cabotegravir for HIV prevention: web annex E: predicted effects of introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling studyPublications · 26 juillet 2022
4719Update on the transition to dolutegravir-based antiretroviral therapy: report of a WHO meeting, 29–30 March 2022Publications · 26 juillet 2022
4720Série de publications techniques sur l’adaptation aux répercussions du climat sur la santé : dénutritionPublications · 25 juillet 2022